Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Proc Natl Acad Sci U S A ; 109(8): 2984-8, 2012 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-22308437

RESUMO

The genetic effects of human exposure to anticancer drugs remain poorly understood. To establish whether exposure to anticancer drugs can result not only in mutation induction in the germ line of treated animals, but also in altered mutation rates in their offspring, we evaluated mutation rates in the offspring of male mice treated with three commonly used chemotherapeutic agents: cyclophosphamide, mitomycin C, and procarbazine. The doses of paternal exposure were approximately equivalent to those used clinically. Using single-molecule PCR, the frequency of mutation at the mouse expanded simple tandem repeat locus Ms6-hm was established in DNA samples extracted from sperm and bone marrow of the offspring of treated males. After paternal exposure to any one of these three drugs, expanded simple tandem repeat mutation frequencies were significantly elevated in the germ line (sperm) and bone marrow of their offspring. This observed transgenerational instability was attributed to elevated mutation rates at the alleles derived from both the exposed fathers and from the nonexposed mothers, thus implying a genome-wide destabilization. Our results suggest that paternal exposure to a wide variety of mutagens can result in transgenerational instability manifesting in their offspring. Our data also raise important issues concerning delayed transgenerational effects in the children of survivors of anticancer therapy.


Assuntos
Antineoplásicos/efeitos adversos , Instabilidade Genômica/efeitos dos fármacos , Instabilidade Genômica/genética , Hereditariedade/efeitos dos fármacos , Hereditariedade/genética , Animais , Feminino , Loci Gênicos/efeitos dos fármacos , Loci Gênicos/genética , Mutação em Linhagem Germinativa/efeitos dos fármacos , Mutação em Linhagem Germinativa/genética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Taxa de Mutação , Linhagem , Sequências de Repetição em Tandem/efeitos dos fármacos , Sequências de Repetição em Tandem/genética
3.
PLoS One ; 6(3): e17877, 2011 Mar 17.
Artigo em Inglês | MEDLINE | ID: mdl-21437292

RESUMO

To our knowledge, there is no report on long-term reproductive and developmental side effects in the offspring of mothers treated with a widely used chemotherapeutic drug such as doxorubicin (DXR), and neither is there information on transmission of any detrimental effects to several filial generations. Therefore, the purpose of the present paper was to examine the long-term effects of a single intraperitoneal injection of DXR on the reproductive and behavioral performance of adult female mice and their progeny. C57BL/6 female mice (generation zero; G0) were treated with either a single intraperitoneal injection of DXR (G0-DXR) or saline (G0-CON). Data were collected on multiple reproductive parameters and behavioral analysis for anxiety, despair and depression. In addition, the reproductive capacity and health of the subsequent six generations were evaluated. G0-DXR females developed despair-like behaviors; delivery complications; decreased primordial follicle pool; and early lost of reproductive capacity. Surprisingly, the DXR-induced effects in oocytes were transmitted transgenerationally; the most striking effects being observed in G4 and G6, constituting: increased rates of neonatal death; physical malformations; chromosomal abnormalities (particularly deletions on chromosome 10); and death of mothers due to delivery complications. None of these effects were seen in control females of the same generations. Long-term effects of DXR in female mice and their offspring can be attributed to genetic alterations or cell-killing events in oocytes or, presumably, to toxicosis in non-ovarian tissues. Results from the rodent model emphasize the need for retrospective and long-term prospective studies of survivors of cancer treatment and their offspring.


Assuntos
Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Hereditariedade/efeitos dos fármacos , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacologia , Ansiedade/tratamento farmacológico , Atrofia , Comportamento Animal/efeitos dos fármacos , Deleção Cromossômica , Cromossomos de Mamíferos/genética , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Doxorrubicina/farmacologia , Doxorrubicina/uso terapêutico , Feminino , Hereditariedade/genética , Hereditariedade/fisiologia , Humanos , Lisofosfolipídeos/farmacologia , Lisofosfolipídeos/uso terapêutico , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Miométrio/efeitos dos fármacos , Miométrio/patologia , Oócitos/efeitos dos fármacos , Folículo Ovariano/efeitos dos fármacos , Folículo Ovariano/patologia , Folículo Ovariano/transplante , Ovulação/efeitos dos fármacos , Fenótipo , Reprodução/efeitos dos fármacos , Espermatozoides/efeitos dos fármacos , Esfingosina/análogos & derivados , Esfingosina/farmacologia , Esfingosina/uso terapêutico , Útero/efeitos dos fármacos , Útero/patologia , Proteína X Associada a bcl-2/deficiência , Proteína X Associada a bcl-2/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA